FDA Investigates Dupixent Link to Rare Skin Cancer

FDA Launches Dupixent Cancer Investigation

The FDA is investigating potential links between Dupixent (dupilumab), a blockbuster medication for eczema and other conditions, and cutaneous T-cell lymphoma (CTCL), a rare but serious skin cancer.

Key Findings

Recent studies have revealed alarming statistics:

4.1x increased risk of CTCL in atopic dermatitis patients using Dupixent
The drug generates over $11 billion in annual sales
Millions of patients potentially affected

What is Dupixent?

Dupixent is prescribed for:

Atopic dermatitis (eczema)
Asthma
Chronic rhinosinusitis with nasal polyps
Eosinophilic esophagitis

Concerning Pattern

Medical experts have identified a troubling pattern where CTCL may be misdiagnosed as eczema, potentially masking the cancer while patients continue Dupixent treatment.

Strong Case Indicators

Individuals with the strongest potential claims typically have:

Age 60 or older
12+ months of Dupixent usage
Initial eczema diagnosis that was later determined to be cancer
CTCL diagnosis following Dupixent treatment

What This Means for Patients

If you have taken Dupixent and developed skin cancer or unusual skin symptoms, you should:

Consult with your doctor immediately
Request a thorough evaluation for CTCL
Consider speaking with a legal professional about your options

Next Steps

The FDA investigation is ongoing, but patients who have been harmed may not need to wait for regulatory action to pursue compensation. Contact a legal professional for a free, confidential case review.